Comprehensive assessment for miRNA polymorphisms in hepatocellular cancer risk: a systematic review and meta-analysis

MiRNA polymorphisms had potential to be biomarkers for hepatocellular cancer (HCC) susceptibility. Recently, miRNA single nucleotide polymorphisms (SNPs) were reported to be associated with HCC risk, but the results were inconsistent. We performed a systematic review with a meta-analysis for the association of miRNA SNPs with HCC risk. Thirty-seven studies were included with a total of 11821 HCC patients and 15359 controls in this meta-analysis. We found hsa- mir-146a rs2910164 was associated with a decreased HCC risk in the recessive model ( P =0.017, OR = 0.90, 95% confidence interval (CI) = 0.83-0.98). While hsa- mir-34b/c rs4938723 was related with an increased HCC risk in the co-dominant model ( P =0.016, odds ratio (OR) = 1.19, 95%CI = 1.03-1.37). When analyzing the Hepatitis B virus (HBV)-related HCC risk, hsa- mir-196a-2 rs11614913 was associated with a decreased HBV-related HCC risk in the co-dominant and allelic models. And hsa- mir-149 rs2292832 was found to be associated with a decreased HBV-related HCC risk in the dominant and recessive models. In conclusion, hsa- mir-146a rs2910164 and hsa- mir-34b/c rs4938723 could be biomarkers for the HCC risk while hsa- mir-196a-2 rs11614913 and hsa- mir-149 rs2292832 had potential to be biomarkers for HBV-related HCC risk.